Title of Invention: Hydrazone derivatives for preventing or treating EBV-related cancers Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2− and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus. Detailed Description: Part general_description_paragraphs: Part FIELD OF INVENTION: The present invention relates to novel hydrazone derivatives, in particular cationic N-acylhydrazone derivatives, useful for treating or preventing cancers associated with the Epstein-Barr Virus (EBV-related cancers) by interfering with the interaction between the host cell protein nucleolin (NCL) and the virus-encoded EBNA1 mRNA in order to unveil tumour cells from EBV-related cancers to the immune system. Part TECHNOLOGICAL BACKGROUND: The Epstein-Barr virus (EBV) is the first oncogenic virus discovered in human and has been linked to various cancers that include Burkitt and Hodgkin lymphomas and 10% of gastric cancers. Another example is the nasopharyngeal carcinoma which is particularly frequent among men in China and Tunisia. Like all the gammaherpesviruses, EBV evades the host immune system but has an Achilles heel: its genome maintenance protein (GMP) EBNA1. Indeed, EBNA1 is essential for EBV genome replication and maintenance and as such expressed in all dividing EBV-infected cells. On the other hand, EBNA1 is highly antigenic and CD8+ T cells directed towards EBNA1 epitopes exist in all infected individuals. Hence, EBV has evolved a mechanism to limit EBNA1 production to the minimal level required for the viral genome replication and, at the same time, to minimize the production of EBNA1-derived antigenic peptides presented to the cytotoxic T cells through the MHC class I pathway. The central glycine-alanine repeat (GAr) of EBNA1 plays a critical role in this mechanism of immune evasion as it is able to self-inhibit the translation of its own mRNA in cis. The high level of EBNA1 protein and the efficient T cell response following the infection by an EBV strain encoding a truncated version of EBNA1 in which GAr has been deleted (EBNA1ΔGAr) demonstrates the critical role of GAr in EBNA1 immune evasion. Of note, a polymorphism in the length of GAr exists and, importantly, the effect of GAr is length-dependent as a longer domain displays a stronger inhibitory effect on both mRNA translation and antigen presentation. The GAr-encoding mRNA sequence is GC rich and forms predicted G-quadruplex (G4) structures that have been implicated in the regulation of EBNA1 synthesis in vitro (Murat et al. Curr Opin Genet Dev 2014, 25, 22-29). G4 are particular secondary structures of nucleic acid formed by the stacking of G-quartets which correspond to a planar arrangement of 4 guanines connected by Hoogsteen hydrogen bonds. G4 structures within G-rich DNA or RNA sequences have been implicated in gene regulation where they can affect transcription, alternative splicing and translation. G4 modes of action are still relatively unknown but cellular factors that can interact with these structures are emerging. GAr-based EBNA1 immune evasion is considered a relevant therapeutic target to treat EBV-related cancers as most tumor cells from EBV-related cancers are infected by EBV whereas, in healthy individuals, the latent infection by EBV is primarily restricted to a specific small pool of memory B cells. Hence, overcoming GAr-based self-inhibition of EBNA1 translation should unveil EBV-carrying tumor cells to cytotoxic T cells without having significant effect on the vast majority of healthy host cells. A yeast-based (Saccharomyces cerevisiae) assay that recapitulates all the aspects of the GAr-based inhibition of translation, including the GAr-length dependency, has been developed, that allowed understanding the mechanisms of GAr-mediated mRNA translation—suppression in cis, as well as the cellular factors involved (Lista et al. Biotechnol J 2015, 10, 1670-1681). This assay was successfully used to identify small molecular weight compounds that can stimulate EBNA1 expression both in yeast and mammalian cells and that relieve GAr-based limitation of antigen presentation (Voisset et al. Dis Model Mech 2014, 7, 435-444). Nucleolin (NCL) is a multifunctional DNA/RNA-binding protein widely conserved among eukaryotes. It is involved in RNA metabolism, in particular in rRNA maturation. NCL binds to G-rich sequences in coding and non-coding regions of various mRNA, many of which encode cancer-related proteins, and enhance their translation. In addition, NCL binds to some G4 structures within DNAs and RNAs. For example, it has been recently shown that NCL binds to and stabilizes G4 structures formed within the LTR promoter of HIV, thereby silencing the provirus transcription (Tosoni et al. Nucleic Acids Res 2015, 43, 8884-8897). NCL also affects the transcription of c-MYC by binding to and stabilizing G4 present in the promoter of this oncogene and that negatively regulate its activity. Based on the yeast assay mentioned above, the Inventors have performed a genetic screen to identify host cell genes involved in the GAr-mediated inhibition of translation. This way, the yeast NSR1 gene encoding the orthologue of human NCL was identified, and it was shown that NCL is critically involved in GAr-based limitation of translation and antigen presentation, and thus in EBNA1 immune evasion. As a result, the NCL-EBNA1 mRNA interaction appears as a relevant therapeutic target for the treatment and/or prevention of EBV-related cancers (see Lista et al., Nat Commun 2017, 8, 16043), and it was shown that PhenDC3 is able to prevent NCL from binding to G4 formed in the GAr mRNA sequence, and to stimulate GAr-limited translation and antigen presentation. There however remains a need for identifying new therapeutic targets, which would disrupt the GAr-based EBNA1 immune evasion of EBV when interacted with by therapeutic agents. Such therapeutic agents, able to interact with these new targets, would thus be useful in the treatment and/or prevention of EBV-related cancers. Part SUMMARY OF THE INVENTION: In this context, the Inventors identified novel hydrazone derivatives, in particular cationic N-acylhydrazone derivatives, which were shown to interact with G4 formed in the GAr mRNA sequence involved in the translation of EBNA1, and which yielded positive results in the yeast assay mentioned above. Therefore, in a first aspect, the present invention relates to a compound of formula (I), or a hydrate or a solvate thereof: wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Ra is C1-C6 alkyl, optionally substituted with a OH group, a O—(C1-C4)alkyl group, or a monocyclic or bicyclic 5- to 10-membered aromatic or heteroaromtic group, Rb is a hydrogen atom, a halogen atom, C1-C6 alkyl optionally substituted with a OH group, or a O—(C1-C4)alkyl group, Y1 and Z1 are independently CH or N+—Rc, provided that al least one of Y1 and Z1 is N+—Rc+ and at least one of Y1 and Z1 is CH, Rc is C1-C6 alkyl, optionally substituted with a OH group, a O—(C1-C4)alkyl group, or a monocyclic or bicyclic 5- to 10-membered aromatic or heteroaromtic group, X2− is one or a plurality of pharmaceutically acceptable anion(s), selected so as to obtain an overall electrically neutral salt, L is (A), (B), (C), (D) or (E): m, n, p, t, u and v may be identical or different and are each independently an integer selected from 0 to 2; q, r and s may be identical or different and are each independently an integer selected from 0 to 3; R1 to R9 may be identical or different and are each independently a halogen atom, a C1-C6 alkyl group, a C3-C8 cycloalkyl group, a O(C1-C6)alkyl group, a NR10R11 group, a C2-C6 alkenyl group, a C5-C8 cycloalkenyl group, said C1-C6 alkyl group, C3-C8 cycloalkyl group, O(C1-C6)alkyl group, C2-C6 alkenyl group, or C5-C8 cycloalkenyl group being optionally substituted with one to three halogen atoms, a OH group, a O—(C1-C6)alkyl group, a NH—(C1-C6)alkyl group or a NHC(O)—R′; R10 and R11 may be identical or different and are each independently: a hydrogen atom, a C1-C6 alkyl group optionally substituted with a OH group, a O—(C1-C6)alkyl group, a NH—(C1-C6)alkyl group or a NHC(O)R′— group; or NR10R11, taken together, form a 3- to 8-membered heterocycloalkyl or 5- to 8-membered heterocycloalkenyl; R′ is a (C1-C6)alkyl group optionally substituted with a C5-C10 aryl group, wherein said C5-C10 aryl group is optionally substituted with a halogen atom, a C1-C6 alkyl group, a O(C1-C6)alkyl group, a C2-C8 alkenyl group, a C5-C8 cycloalkenyl group, a 3- to 8-membered heterocycloalkyl, a 5- to 8-membered heterocycloalkenyl, a N((C1-C6)alkyl)2 group or a N((C1-C6)haloalkyl)2 group. In a preferred embodiment, L is (A), (C) or (E): provided that Ar1 and Ar2 are not groups of formula (II) when L is (C) or (E), m, n, p, u and v may be identical or different and are each independently an integer selected from 0 to 2; s is an integer selected from 0 to 3; R1, R2, R3, R6, R3 and R9 may be identical or different and are each independently a halogen atom, a C1-C6 alkyl group, a C3-C8 cycloalkyl group, a O(C1-C6)alkyl group, a NR10R11 group, a C2-C6 alkenyl group, a C5-C8 cycloalkenyl group said C1-C6 alkyl group, C3-C8 cycloalkyl group, O(C1-C6)alkyl group, C2-C6 alkenyl group, or C5-C8 cycloalkenyl group being optionally substituted with one to three halogen atoms, a OH group, a O—(C1-C6)alkyl group, a NH—(C1-C6)alkyl group or a NHC(O)—R′; R10 and R11 may be identical or different and are each independently: a hydrogen atom, a C1-C6 alkyl group optionally substituted with a OH group, a —(C1-C6)alkyl group, a NH—(C1-C6)alkyl group or a NHC(O)—R′, or NR10R11, taken together, form a 3- to 8-membered heterocycloalkyl or 5- to 8-membered heterocycloalkenyl, R′ is a (C5-C6)alkyl group optionally substituted with a C5-C10 aryl group, wherein said C5-C10 aryl group is optionally substituted with a halogen atom, a C1-C8 alkyl group, a O(C1-C6)alkyl group, a C2-C8 alkenyl group, a C5-C8 cycloalkenyl group, a 3- to 8-membered heterocycloalkyl, a 5- to 8-membered heterocycloalkenyl, a N((C1-C6)alkyl)2 group or a N((C1-C6)haloalkyl)2 group. Advantageously, compounds of formula (I) according to the present invention do not include any metal complex or coordination compound. For the purpose of the invention, the term □pharmaceutically acceptable□ is intended to mean what is useful to the preparation of a pharmaceutical composition, and what is generally safe and non-toxic, for a pharmaceutical use. The term □pharmaceutically acceptable salt□ is intended to mean, in the framework of the present invention, a salt of a compound which is pharmaceutically acceptable, as defined above, and which possesses the pharmacological activity of the corresponding compound. In another aspect, the present invention relates to a composition comprising: as active ingredient, the compound of formula (I) as described above or below, or a hydrate or a solvate thereof, and optionally another therapeutic agent selected from antibiotics, anticancer agents, steroidal and non-steroidal anti-inflammatory drugs, and a pharmaceutically acceptable excipient. In another aspect, the present invention relates to a kit comprising at least: a first composition comprising the compound of formula (I) as defined above or below, and a pharmaceutically acceptable excipient, and a second composition comprising another therapeutic agent preferably selected from antibiotics, anticancer agents, steroidal and non-steroidal anti-inflammatory drugs, especially as a combination product for simultaneous, staggered or sequential use. In another aspect, the present invention relates to the compounds or the compositions of the invention or the kit of the invention for use as drug, in particular for treating an Epstein-Barr-Virus (EBV)-related cancer. In another aspect, the present invention relates to the use of a compound of formula (I) as defined above or below, or a hydrate or a solvate thereof, or the composition or kit of the invention, for the manufacture of a medicament for preventing or treating an EBV-related cancer. In another aspect, the present invention relates to a method for preventing or treating an EBV-related cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) as defined above or below, or a hydrate or a solvate thereof, or the composition or the kit of the invention. In another aspect, the present invention relates to a process for preparing the compounds of formula (I) as defined above or below. Part DETAILED DESCRIPTION: Compounds of Formula (I) L Preferably, L is (A), (C), (D) or (E), more preferably L is (A), (C) or (E), even more preferably L is (A) or (C). In a particular embodiment, L is (C) and s is 0, or L is (A), and m and p are 0, and n is 0 or 1, or m and n are 0, and p is 0 or 1, or n is 0, and m and p are identical and are 0 or 1, or m, n and p are 0. In another particular embodiment, L is (B) and q and r are 0, or L is (D) and t is 0, or L is (E) and u and v are 0. In a particular embodiment, R1 to R9 may be identical or different and are each independently a halogen atom, a C1-C6 alkyl group, a O(C1-C6)alkyl group, or a NR10R11 group, said C1-C6 alkyl group or O(C1-C6)alkyl group, group being optionally substituted with one of two halogen atoms, a OH group, a O—(C1-C6)alkyl group, a NH—(C1-C6)alkyl group or a NHC(O)—R′ group; R10 and R11 may be identical or different and are each independently: a hydrogen atom, a C1-C5 alkyl group optionally substituted with a OH group, a O—(C1-C6)alkyl group, a NH—(C1-C6)alkyl group or a NHC(O)R′— group; or NR10R11, taken together, form a 3- to 8-membered heterocycloalkyl; R′ is as defined above or below. Advantageously, R′ is a (C1-C6)alkyl group optionally substituted with a 5- to 10-membered aryl group, wherein said 5- to 10-membered aryl group is optionally substituted with a halogen atom, a C1-C6 alkyl group, a O(C1-C6)alkyl group, a 3- to 8-membered heterocycloalkyl, a 5- to 8-membered heterocycloalkenyl, a N((C1-C6)alkyl)2 group or a N((C1-C6)haloalkyl)2 group. In a particular embodiment, R1 to R9 may be identical or different and are each independently a halogen atom, a C1-C6 alkyl group, a C3-C8 cycloalkyl group, a O(C1-C6)alkyl group, a NR10R11 group, a C2-C6 alkenyl group, a C5-C8 cycloalkenyl group; R10 and R11 may be identical or different and are each independently: a hydrogen atom, a C1-C6 alkyl group optionally substituted with a OH group, a O—(C1-C6)alkyl group, a NH—(C1-C6)alkyl group, or NR10R11, taken together, form a 3- to 8-membered heterocycloalkyl or 5- to 8-membered heterocycloalkenyl. Ar1, Ar2 In a particular embodiment, Ra is C1-C6 alkyl, optionally substituted with a OH group, a O—(C1-C4)alkyl group or a monocyclic 5- or 6-membered aromatic or heteroaromtic group, such as a phenyl or a pyridine group. Advantageously, Ra is C1-C4 alkyl, optionally substituted with a OH group, a O—(C1-C4)alkyl group or a monocyclic 5- or 6-membered aromatic or heteroaromtic group, such as a phenyl or a pyridine group. Preferably, Ra is C1-C4 alkyl, optionally substituted with a monocyclic 5- or 6-membered aromatic or heteroaromtic group, such as a phenyl or a pyridine group. Most preferably, Ra is an ethyl, a methyl group or a benzyl group. In a particular embodiment, Rb is a hydrogen atom, a halogen atom, C1-C6 alkyl optionally substituted with a OH group, or a O—(C1-C4)alkyl group, preferably Rb is a hydrogen atom or a halogen atom, most preferably Rb is a hydrogen atom. In a particular embodiment, Rc is C1-C6 alkyl, optionally substituted with a OH group, a O—(C1-C4)alkyl group or a monocyclic 5- or 6-membered aromatic or heteroaromtic group, such as a phenyl or a pyridine group. Advantageously, Rc is C1-C4 alkyl, optionally substituted with a OH group, a O—(C1-C4)alkyl group or a monocyclic 5- or 6-membered aromatic or heteroaromtic group, such as a phenyl or a pyridine group. Preferably, Rc is C1-C4 alkyl, optionally substituted with a monocyclic 5- or 6-membered aromatic or heteroaromtic group, such as a phenyl or a pyridine group. Most preferably, Rc is an ethyl, a methyl group or a benzyl group. In a particular embodiment, Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II′), (III′) and (III″): with Ra, Rb and Rc as defined above or below. In a particular embodiment, Ar1 and/or Ar2 are of formula (II) or (II′), Ra is a linear C1-C4 alkyl optionally substituted with a phenyl group (preferably an ethyl, a methyl group or a benzyl group), and Rb is a hydrogen or halogen atom, preferably a hydrogen atom. Preferably, in this embodiment, Ar1 and/or (advantageously and) Ar2 are of formula (II′), Ra is a ethyl, a methyl group or a benzyl group and Rb is a hydrogen atom. In another preferred embodiment, Ar1 and/or Ar2 are of formula (III′) or (III″), and Rc is a linear C1-C4 alkyl optionally substituted with a phenyl group, preferably an ethyl, a methyl group or a benzyl group. Preferably, in this embodiment, Ar1 and/or (advantageously and) Ar2 are of formula (III′), and Rc is an ethyl, a methyl group or a benzyl group. X2− As stated above, X2− is one or a plurality of pharmaceutically acceptable anion(s), selected so as to obtain an overall electrically neutral (pharmaceutically acceptable) salt. The nature of the anion may vary, provided that it is pharmaceutically acceptable, and yields a pharmaceutically acceptable salt. Suitable pharmaceutically acceptable anions may be prepared from the corresponding base of an inorganic acid or an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic, hydroxybutyric, salicylic, galactaric and galacturonic acid. The salts of the compounds of formula (I) may be prepared by conventional methods from the corresponding compound, for example, using an anion-exchange resin, pre-treated with the appropriate acid, optionally in the form of a metallic or alkaline or alkaline earth base, with any of the compounds of the invention. Advantageously, according to the present invention, X2− is not a metallic ion. Compounds of the present invention do not include metal complexes or coordination compounds. Typically, X2− represents one or a plurality (generally 2) anion(s) as defined above with two negative charges. Advantageously, X2− represents 2 anions selected from the group consisting of a halogenide, a carboxylate, a C1-C6alkylsulfonate, a C1-C6haloalkylsulfonate and an alkylarylsulfonate, preferably a halogenide, a methanesulfonate, a trifluoromethanesulfonate or a tosylate. For instance, X2− represents 2 anions selected from the group consisting of Cl−, Br−, I−, and CF3SO3−, such as Br−, I−, and CF3SO3−. Combinations When L is (C) or (D), then Ar1 and Ar2 are identical or different and are advantageously of formula (III). When Ar1 and/or Ar2 is of formula (II), then L is preferably of formula (A), (B), or (E), more preferably of formula (A) or (E). For instance, when Ar1 and/or Ar2 is of formula (II), L is of formula (A). In a preferred embodiment, the compound of formula (I) is characterized in that: Ar1 and Ar2 are identical and selected from the group consisting of groups of formula (II′), (III′) and (III□), Ra is C1-C6 alkyl, optionally substituted with a OH group, a O—(C1-C4)alkyl group or a monocyclic or bicyclic 5- to 10-membered aromatic or heteroaromatic group, preferably Ra is ethyl, methyl or benzyl, Rb is a hydrogen atom, Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, Rc is C1-C6 alkyl, optionally substituted with a OH group, a O—(C1-C4)alkyl group, or a monocyclic or bicyclic 5- to 10-membered aromatic or heteroaromtic group, preferably Rc is ethyl, methyl or benzyl, X2− is one or a plurality of pharmaceutically acceptable anion(s), selected so as to obtain an overall electrically neutral salt, preferably 2 I− or 2 Br−, L is (A), (C), (D) or (E), m, n, p, t, u and v may be identical or different and are each independently an integer selected from 0 to 2; s is an integer selected from 0 to 3; R1 to R9 may be identical or different and are each independently a halogen atom, a C1-C6 alkyl group, a C3-C8 cycloalkyl group, a O(C1-C6)alkyl group, a NR10R11 group, a C2-C6 alkenyl group, a C5-C8 cycloalkenyl group; R10 and R11 may be identical or different and are each independently: a hydrogen atom, a C1-C6 alkyl group optionally substituted with a OH group, a O—(C1-C6)alkyl group, a NH—(C1-C6)alkyl group, or NR10R11, taken together, form a 3- to 8-membered heterocycloalkyl or 5- to 8-membered heterocycloalkenyl. In this preferred embodiment, Ar1 and Ar2 are preferably identical, and of formula (II′), (III′) or (III□). In this preferred embodiment, advantageously, L is (C) and s is 0, or L is (A), and m and p are 0, and n is 0 or 1, or m and n are 0, and p is 0 or 1, or n is 0, and m and p are identical and are 0 or 1, or m, n and p are 0. Preferably, in this embodiment, m, n, p, s, t, u and v are all 0. In another preferred embodiment, the compound of formula (I) is characterized in that: Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III), Ra is C1-C6 alkyl, optionally substituted with a OH group, a O—(C1-C4)alkyl group or a monocyclic or bicyclic 5- to 10-membered aromatic or heteroaromatic group, preferably Ra is a linear C1-C4 alkyl optionally substituted with a phenyl group, more preferably Ra is an ethyl, a methyl or a benzyl group, Rb is a hydrogen atom, a halogen atom, C1-C6 alkyl optionally substituted with a OH group, or a O—(C1-C4)alkyl group, preferably Rb is a hydrogen or halogen atom, more preferably Rb is a hydrogen atom, Y1 and Z1 are independently CH or N+—Rc, provided that al least one of Y1 and Z1 is N+—Rc+ and at least one of Y1 and Z1 is CH, Rc is C1-C6 alkyl, optionally substituted with a OH group, a O—(C1-C4)alkyl group, or a monocyclic or bicyclic 5- to 10-membered aromatic or heteroaromtic group, preferably Rc a linear C1-C4 alkyl optionally substituted with a phenyl group, more preferably Rc is an ethyl, a methyl or a benzyl group, X2− is one or a plurality of pharmaceutically acceptable anion(s), selected so as to obtain an overall electrically neutral salt, preferably X2− represents two anions selected from the group consisting of a halogenide, a carboxylate, a C1-C6alkylsulfonate, a C1-C6haloalkylsulfonate and an alkylarylsulfonate, more preferably X2− is 2 I− or 2 Br−, L is (A), (C) or (E), provided that Ar1 and Ar2 are not groups of formula (II) when L is (C) or (E), m, n, p, u and v may be identical or different and are each independently an integer selected from 0 to 2; s is an integer selected from 0 to 3; R1, R2, R3, R6, R3 and R9 may be identical or different and are each independently a halogen atom, a C1-C6 alkyl group, a C3-C8 cycloalkyl group, a O(C1-C6)alkyl group, a NR10R11 group, a C2-C8 alkenyl group, a C5-C8 cycloalkenyl group said C1-C6 alkyl group, C3-C8 cycloalkyl group, O(C1-C6)alkyl group, C2-C6 alkenyl group, or C5-C8 cycloalkenyl group being optionally substituted with one to three halogen atoms, a OH group, a O—(C1-C6)alkyl group, a NH—(C1-C6)alkyl group or a NHC(O)—R′; R10 and R11 may be identical or different and are each independently: a hydrogen atom, a C1-C6 alkyl group optionally substituted with a OH group, a O—(C1-C6)alkyl group, a NH—(C1-C6)alkyl group or NHC(O)—R′, or NR10R11, taken together, form a 3- to 8-membered heterocycloalkyl or 5- to 8-membered heterocycloalkenyl, R′ is a (C1-C5)alkyl group optionally substituted with a C5-C10 aryl group, wherein said C5-C10 aryl group is optionally substituted with a halogen atom, a C1-C6 alkyl group, a O(C1-C6)alkyl group, a C2-C6 alkenyl group, a C5-C8cycloalkenyl group, a 3- to 8-membered heterocycloalkyl, a 5- to 8-membered heterocycloalkenyl, a N((C1-C6)alkyl)2 group or a N((C1-C6)haloalkyl)2 group. Advantageously, Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of formula (II), (III′) and (III□). In this preferred embodiment, advantageously L is (C), s is 0 and Ar1 and Ar2 are preferably identical, and of formula (III), preferably of formula (III′) or (III□), or L is (A), Ar1 and Ar2 are preferably identical, and of formula (II) or (III), preferably of formula (I′), (III′) or (III□) and m and p are 0, and n is 0 or 1, or m and n are 0, and p is 0 or 1, or n is 0, and m and are identical and are 0 or 1, or m, n and p are 0. Preferably, in this embodiment, m, n, p, s, t, u and v are all 0. Exemplary cationic compounds of formula (I) are as follows: Ar1 and Ar2 are No L identical and are both 1a with Rb being H and Ra being methyl 1b with Rb being H and Ra being ethyl 1c with Rb being H and Ra being benzyl 2a with Rc being methyl 2b with Rc being ethyl 2c with Rc being benzyl 3a with Rc being methyl 3b with Rc being ethyl 3c with Rc being benzyl 4a with Rb being H and Ra being methyl 4b with Rb being H and Ra being ethyl 4c with Rb being H and Ra being benzyl 5a with Rc being methyl 5b with Rc being ethyl 5c with Rc being benzyl 6a with Rc being methyl 6b with Rc being ethyl 6c with Rc being benzyl 7a with Rb being H and Ra being methyl 7b with Rb being H and Ra being ethyl 7c with Rb being H and Ra being benzyl 8a with Rc being methyl 8b with Rc being ethyl 8c with Rc being benzyl 9a with Rc being methyl 9b with Rc being ethyl 9c with Rc being benzyl 10a with Rb being H and Ra being methyl 10b with Rb being H and Ra being ethyl 10c with Rb being H and Ra being benzyl 11a with Rc being methyl 11b with Rc being ethyl 11c with Rc being benzyl 12a with Rc being methyl 12b with Rc being ethyl 12c with Rc being benzyl with X2− as defined above, especially representing 2 anions selected from the group consisting of a halogenide, a carboxylate, a C1-C6alkylsulfonate, a C1-C6haloalkylsulfonate and an alkylarylsulfonate, preferably a halogenide, a methanesulfonate, a trifluoromethanesulfonate or a tosylate for instance, 2 anions selected from the group consisting of Cl−, Br−, I−, and CHF3SO3−, such as Br−, I−, and CHF3SO3−, preferably Br− or I−. The preferred exemplary cationic compounds of formula (I) are as follows: Ar1 and Ar2 are No L identical and are both 2a with Rc being methyl 2b with Rc being ethyl 2c with Rc being benzyl 3a with Rc being methyl 3b with Rc being ethyl 3c with Rc being benzyl 8a with Rc being methyl 8b with Rc being ethyl 8c with Rc being benzyl 9a with Rc being methyl 9b with Rc being ethyl 9c with Rc being benzyl 10a with Rb being H and Ra being methyl 10b with Rb being H and Ra being ethyl 10c with Rb being H and Ra being benzyl 11a with Rc being methyl 11b with Rc being ethyl 11c with Rc being benzyl 12a with Rc being methyl 12b with Rc being ethyl 12c with Rc being benzyl with X2− as defined above, especially representing 2 anions selected from the group consisting of a halogenide, a carboxylate, a C1-C6alkylsulfonate, a C1-C6haloalkylsulfonate and an alkylarylsulfonate, preferably a halogenide, a methanesulfonate, a trifluoromethanesulfonate or a tosylate for instance, 2 anions selected from the group consisting of Cl−, Br−, I−, and CHF3SO3−, such as Br−, I−, and CHF3SO3−, preferably Br− or I−. In an advantageous embodiment, the compound is compound 2a, 2b, 2c, 3a, 3b, 3c, 5a, 5b, 5c, 6a, 6b, 6c, 7a, 7b, 7c, 8a, 8b, 8c, 9a, 9b, 9c, 10a, 10b, 10c, 11a, 11b, 11c, 12a, 12b, 12c, such as compound 2a, 2b, 2c, 3a, 3b, 3c, 7a, 7b, 7c, 8a, 8b, 8c, 9a, 9b, 9c, 10a, 10b, 10c, 11a, 11b, 11c, 12a, 12b, 12c, preferably compound 2a, 2b, 2c, 3a, 3b, 3c, 8a, 8b, 8c, 9a, 9b, 9c, 10a, 10b, 10c, 11a, 11b, 11c, 12a, 12b, 12c with X2− as defined above, especially representing 2 anions selected from the group consisting of a halogenide, a carboxylate, a C1-C6alkylsulfonate, a C1-C6haloalkylsulfonate and an alkylarylsulfonate, preferably a halogenide, a methanesulfonate, a trifluoromethanesulfonate or a tosylate for instance, 2 anions selected from the group consisting of Br− or I−. Advantageously, the compound of the invention is compound 2a, 2c, 3b, 3c, 8a, 8c, 9b, 9c, 10a, 11a, 11c, 12b, 12c, in particular it is compound 2a, 2c, 10a, 11a, 11c with X2− representing 2 anions selected from the group consisting of Br− or I−. Advantageously, the compound of the invention is: preferably 2a, 2c, 10a, 11a, and 11c, most preferably 2a. Miscellaneous The present invention encompasses only stable compounds. The compounds of formula (I) as described above may exist in tautomeric, diastereomeric or enantiomeric forms. The present invention contemplates all such compounds, including cis- and trans-diastereomers, E- and Z-stereomers, R- and S-enantiomers, diastereomers, d-isomers, l-isomers, the racemic mixtures thereof and other mixtures thereof. Pharmaceutically acceptable salts of such tautomeric, diastereomeric or enantiomeric forms are also included within the invention. The terms “cis” and “trans”, as used herein, denote a form of geometric isomerism in which two carbon atoms connected by a double bond will each have a hydrogen atom on the same side of the double bond (“cis”) or on opposite sides of the double bond (“trans”). Some of the compounds described contain alkenyl groups, and are meant to include both cis and trans or “E” and “Z” geometric forms. Furthermore, where the compounds described contain one or more stereocenters, the present invention includes R, S, and mixtures of R and S forms for each stereocenter present. Process for Preparing the Compounds of Formula (I) A process for preparing the compounds of formula (I) comprises the following successive steps: a) Condensing NH2NH2.H2O (hydrazine hydrate) with an ester of formula (IV), wherein L is as defined above, and Re is a O(C1-C6)alkyl group, said C1-C6 alkyl being optionally substituted with a OH group, a O—(C1-C4)alkyl group or a monocyclic or bicyclic 5- to 10-membered aromatic or heteroaromtic group, to obtain hydrazone (V), with L as defined above, b) Condensing the compound of formula (V) with an aldehyde of formula Ar1′—CHO and/or an aldehyde of formula Ar2′—CHO, Ar1′ and Ar2′ being identical or different and each independently selected from the group consisting of groups of formula (IIa) and (IIIa): with Rb as defined above, Y2 and Z2 being independently CH or N, provided that al least one of Y2 and Z2 is N and at least one of Y2 and Z2 is CH, to obtain Intermediate (VI), with L, Ar1′ and Ar2′ as defined above, and c) Alkylating Intermediate (VI) with an alkylating agent of formula Rd—Z, wherein Z is a leaving group, preferably a halogen atom such as Br or I, and Rd is a C1-C6 alkyl, optionally substituted with a OH group, a O—(C1-C4)alkyl group or a monocyclic or bicyclic 5- to 10-membered aromatic or heteroaromtic group, to obtain the compound of formula (I) as defined above. Re is advantageously a O(C1-C4)alkyl group, optionally substituted with a OH, OCH3 or phenyl group, such as a methyl, an ethyl or a benzyl group, preferably a methyl or ethyl group. Compounds of formula (IV) are commercial or easily accessible to the one of skill in the art. They may be prepared by methods known in the art, as described for instance in European patent application no 17305588.0, filed on 19 May 2017 (see for instance page 6 and examples). In particular, compounds of formula (IV) wherein m, n, p, q, r, s, t, u, or v is not 0 may easily be obtained from the corresponding dimethyl heteroarene, oxidized into the corresponding dicarboxylic acid and subsequently converted into a corresponding dimethyl ester of formula (IV). Step a) is preferably performed under heating in a solvent such as an alcohol, preferably ethanol. Step b) is preferably performed under heating in a solvent such as an alcohol, preferably ethanol. Step c) is preferably performed under heating in a polar solvent such as a polar aprotic solvent, in particular dimethylformamide (DMF). In particular, compound 2a is obtained as follows: Pharmaceutical Compositions The pharmaceutically acceptable excipient is selected, according to the dosage form and mode of administration desired, from the typical excipients known to persons skilled in the art. The pharmaceutical compositions according to the invention can be administered parenterally (such as intravenously or intradermally), topically, orally or rectally. The term □parenteral□ as used herein includes subcutaneous, intravenous, intramuscular, intravesical or infusion techniques. Preferably, the term □parenteral□ refers to infusion techniques. For therapeutic purposes, formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. Preferably, the compositions of the invention are administered via oral route. Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compound is ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings. Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents. In order to selectively control the release of the active compound to a particular region of the gastrointestinal tract, the pharmaceutical compositions of the invention may be manufactured into one or several dosage forms for the controlled, sustained or timed release of one or more of the ingredients, as known in the art. The amount of the compound of the invention that may be combined with the excipient materials to produce a single dosage of the composition will vary depending upon the subject and the particular mode of administration, as known in the art. The pharmaceutical composition of the invention may further comprise another one or more therapeutic compounds. Therefore, another aspect of the present invention encompasses a combination of a compound of formula (I) as described above, with one or more therapeutic compounds. The therapeutic compound is preferably selected from antibiotics, anticancer agents, steroidal and non-steroidal anti-inflammatory drugs, advantageously it is an anticancer agent. The antibiotic is preferably selected from the group consisting of beta-lactams, aminoglycosides, tetracyclines, glycylcyclines, macrolides, azalides, ketolides, synergistins, lincosanides, fluoroquinolones, phenicols, rifamycins, sulfamides, trimethoprim, glycopeptides, oxazolidinones, nitromidazoles and lipopeptides. The non-steroidal anti-inflammatory drug is preferably selected from the group consisting of salicylate and salts thereof, Celecoxib, Diclofenac and salts thereof, Diflunisal, Etodolac, Fenoprofen, Flurbiprofen, Ibuprofen, Indomethacin, Ketoprofen, Meclofenamate, Mefenamic acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Piroxicam, Rofecoxib Salsalate, Sulindac, Tolmetin, and Valdecoxib. The steroidal anti-inflammatory drug is preferably selected from the group consisting of Prednisone, Methylprednisolone, Prednisolone, aldosterone, cortisol, cortisone, hydrocortisone, corticosterone, tixocortol, ciclesonide, prednicarbate Triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, halcinonide, Hydrocortisone-17-valerate, halometasone, alclometasone, betamethasone, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone, fluocortolone, fluprednidene acetate, dexamethasone, and mixtures thereof, and the corresponding salts or hydrates thereof. The anticancer agent is preferably cisplatine, methotrexate, cyclophosphamide, doxorubicin, fluorouracil. In some embodiments, the combination comprises 1, 2, 3, 4, or 5 therapeutic compounds, preferably one therapeutic compound. In another aspect, the present invention relates to a kit comprising at least: a first composition comprising the compound of formula (I) as defined above or below, and a pharmaceutically acceptable excipient, and a second composition comprising another therapeutic agent, preferably selected from antibiotics, anticancer agents, steroidal and non-steroidal anti-inflammatory drugs, advantageously an anticancer agent, as a combination product for simultaneous, staggered or sequential use. The kit of the invention is used as drug, in particular for treating an EBV-related cancer. The antibiotics, anticancer agent, steroidal and non-steroidal anti-inflammatory drug is in particular as listed above in connection with the pharmaceutical composition for use of the invention. Therapeutic Use The compound or the composition or the kit of the invention is useful as a drug, typically for disrupting the GAr-based EBNA1 immune evasion of EBV, in particular by preventing the limitation of EBNA1 production in EBV-infected cells. Consequently, the compound or the composition or the kit of the invention is in particular useful for stimulating the immune response towards EBNA1, and/or EBV-infected cells. As a result, the compound or the composition or the kit of the invention is in particular useful for preventing and/or treating an EBV-related cancer. The mechanism of action of the compound or the composition or the kit of the invention in preventing and/or treating an EBV-related cancer is advantageously related to their binding to G4 structures formed by mRNA and EBNA1. Such a mechanism is demonstrated by the results of in vitro experiments showing the binding of the compounds of the present invention to G4-EBNA1 structures. Contrary to the prior art, the anti-cancer action is not related to complexation of a metal cation such as iron. As used herein, an EBV-related cancer□ is understood as a cancer which is linked to the oncogenic Epstein-Barr virus. In particular, an □EBV-related cancer□ is understood as a cancer wherein more than 50%, typically more than 90%, in particular more than 95% of tumoral cells are infected by EBV, whereas most non tumoral cells are advantageously not infected by EBV. Typically, only some B-cells (memory cells) are also infected by EBV in an EBV-related cancer. Such a profile of infection by EBV explains the specificity of the compounds of the invention in a method for treating EBV-related cancers. Detection of EBV in cancers is routine for the pathologists and is based mainly on three main techniques detailed hereafter. The most sensitive technique is in situ hybridization of EBV-encoded RNAs, so-called EBERS (Weiss, L. M. et al, 1989, Am J Surg Pathol, 13, 625-631; Chang K. L. et al, 1992, Diagn Mol Pathol, 1, 246-255). The presence of EBNA1 and other EBV-related antigens is also commonly used for immunohistochemistry (Grssser, F A et al., 1994, Blood, 84, 3792-3798). These two techniques can be used on frozen or paraffin embedded material. It is also possible to lyse the tumour samples and detect EBV DNA using Polymerase Chain Reaction (Akao et al., 1991, Laryngoscope, 101, 279-283). Therefore, in a particular embodiment, the compound or the composition or the kit of the invention is used in combination, simultaneously, separately or sequentially, with ionizing or non-ionizing radiations or hyperthermia. In particular, said EBV-related cancer is: Hodgkin's lymphoma, Burkitt's lymphoma, Nasopharyngeal carcinoma, some gastric cancers (about 10% are related to EBV infection), lymphomas in immunosuppressed patients (such as AIDS-suffering patients, post-transplant patients), T/NK cell lymphomas (such as nasal T/NK lymphoma, aggressive NK-cell leukaemia, T cell lymphoproliferative disorder of childhood). The □effective dose□ of a compound of the invention varies as a function of numerous parameters such as, for example, the route of administration and the weight, the age, the sex, the advancement of the pathology to be treated and the sensitivity of patient to be treated. As used herein, “patient” includes any mammal, and is preferably a human being. Definitions The term □halogen□, as used in the present invention, refers to a fluorine, bromine, chlorine or iodine atom, preferably a chlorine, bromine or fluorine atom. The term □C1-C6)alkyl□, as used in the present invention, refers to a straight or branched saturated hydrocarbon chain containing from 1 to 6 carbon atoms including, but not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, n-hexyl. The term □(C1-C6)haloalkyl□, as used in the present invention, refers to a straight or branched saturated hydrocarbon chain containing from 1 to 6 carbon atoms substituted with halogen atoms, such as chlorine, bromine, iodine or fluorine atoms, preferably chlorine or fluorine atoms. Examples of (C1-C6)haloalkyl include, but are not limited to, CH2Cl, CH2Br, CH2I, CH2F, CHF2, CF3, CH2CH2Cl, CH2CH2BR, CH2CH2, CH2CH2F. The term □(C2-C6)alkenyl□, as used in the present invention, refers to a straight or branched unsaturated hydrocarbon chain containing from 2 to 6 carbon atoms and comprising at least one double bond including, but not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl. The term □(C3-C8)cycloalkyl□, as used in the present invention, refers to a hydrocarbon monocyclic or bicyclic (fused) ring having 3 to 8 carbon atoms including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl. The term □(C5-C10)cycloalkenyl□, as used in the present invention, refers to a hydrocarbon monocyclic or bicyclic (fused) ring having 5 to 10 carbon atoms and comprising at least one double bond including, but not limited to, cyclopentenyl, cyclohexenyl. The term □heterocycloalkyl□, as used in the present invention, refers to a hydrocarbon monocyclic or bicyclic (fused) ring having 3 to 8 ring atoms, containing at least one heteroatom, preferably 1 or 2 heteratoms, in the ring. The heteroatom is preferably selected from O, N or S, and the S atom may be mono or dioxidized, i.e. the sulphur atom may be S, S(O) or SO2. heterocycloalkyls include, but are not limited to, epoxide, aziridine, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl. The term □heterocycloalkenyl□, as used in the present invention, refers to a hydrocarbon monocyclic or bicyclic (fused) ring having 5 to 8 ring atoms, containing at least one heteroatom, preferably 1 or 2 heteratoms, in the ring, and comprising at least one double bond. The heteroatom is preferably selected from O, N or S, and the S atom may be mono or dioxidized, i.e. the sulphur atom may be S, S(O) or SO2. heterocycloalkenyls include, but are not limited to, pyrrolyl, dihydrofuranyl, dihydrothiophenyl, dihydropyranyl, tetrahydropyridinyl, dihydrooxazinyl, oxindolyl, benzothiazinyl, benzothiazinonyl, phthalimidyl, indolinyle, isoindolinyle. As used herein, an □aryl group□ may be an aromatic or heteroaromatic group. The term “aromatic group” as used herein alone or as part of another group denotes optionally substituted homocyclic aromatic groups, preferably monocyclic or bicyclic (fused) groups, containing from 6 to 10 carbons in the ring portion, such as phenyl, naphthyl and indenyle. Phenyl and naphthyl are the most preferred aromatic groups. The term “heteroaromatic” as used herein alone or as part of another group denotes optionally substituted aromatic groups having at least one heteroatom in at least one ring, and preferably 5 or 6 atoms in each ring. The heteroaromatic group preferably has 1 to 3 heteroatoms preferably selected from O, N and S in the ring, and may be bonded to the remainder of the molecule through a carbon or heteroatom. Exemplary heteroaromatics include furyl, thiophenyl, pyrrolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, isoxindolyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl or naphthyridinyl. Preferably, the heteroaromatic group is selected from a pyridinyl, a pyrimidinyl, quinolinyl, isoquinolinyl, naphthyridinyl. Most preferably, the heteroaromatic group is a pyridine. As used herein, the term □alkylaryl□ refers to a (C1-C6)alkyl-aryl group. Preferably, the alkylaryl group is a (C1-C6)alkyl-aromatic group such as a benzyl group. As used herein, an □alcohol□ is understood as a linear or ramified hydrocarbon compound comprising between 1 and 6 carbon atom, substituted with 1 to 3 OH groups. Preferably, an alcohol is a linear or ramified C1-C6 hydrocarbon compound substituted with 1 OH group, such as methanol, ethanol, n-propanol, isopropanol or n-butanol. The term □leaving group□ as used herein refers to a chemical group which can be easily replaced with a nucleophile during a nucleophilic substitution reaction, the nucleophile being in particular a nitrogen containing heteroaromatic group, such as a pyridinyl or a quinolinyl. Such a leaving group can be in particular a halogen atom or a sulfonate. The sulfonate is in particular a group □OSO2—R10 with R10 representing a (C1-C6)alkyl, aryl, aryl-(C1-C6)-alkyl or (C1-C6)-alkyl-aryl group. The sulfonate may be a mesylate (CH3—S(O2)O—), a triflate (CF3-S(O)2O—) or a tosylate (p-Me-C6H4—S(O)2O—). Preferably, the leaving group is an halogen atom or a mesylate group, more specifically an iodine atom, a bromine atom or a mesylate group. Also, in the present invention, Me stands for methyl and Ph stands for phenyl. More generally, the abbreviations used to refer to chemical groups have the meaning commonly known in the art. Of note, DMSO is an abbreviation for dimethylsulfoxyde. Part EXAMPLES: Part I. Synthesis of Compounds of the Invention: I.1 Synthesis of bis(acylhydrazides) Pyridine-2,6-dicarbohydrazide (L1): A solution of the dimethyl pyridine-2,6-dicarboxylate (10 mmol, 1.95 g) and hydrazine hydrate (220 mmol, 11.2 g, 10.9 mL) in ethanol (150 mL) was heated in the oil bath under reflux for 18 h and then cooled to room temperature. The precipitate was filtered, twice washed with ethanol, once with ether, and dried. White solid, yield 1.73 g (89%); 1H NMR (300 MHz, DMSO-d6): δ=10.63 (s, 2H), 8.13 (s, 3H), 4.63 (s, 4H). MS (ESI+): m/z=196.2 [M+H]+. Pyrimidine-4,6-dicarbohydrazide (L2) was obtained by the same experimental procedure from 4,6-dimethyl pyrimidine-4,6-dicarboxylate. Yield 1.81 g (92%). Pale-yellow solid; 1H NMR (300 MHz, DMSO-d6): δ=10.41 (s, 2H), 9.35 (d, J=1.1 Hz, 1H), 8.35 (d, J=1.1 Hz, 1H), 4.77 (s, 4H); MS (ESI+): m/z=197.1 [M+H]+. 1,8-Naphthyridine-2,7-dicarbohydrazide (L3) was obtained by the same experimental procedure from 2,7-dimethyl-1,8-naphthyridine-2,7-dicarboxylate (which is obtained as described by G. Newkome et al., J Org Chem 1990, 55, 2838□2842). Yield 2.45 g (97%). Pale-yellow solid; 1H NMR (300 MHz, DMSO-d6): δ=10.00 (s, 2H), 8.74 (d, J=8.4 Hz, 2H), 8.25 (d, J=8.4 Hz, 2H), 4.74 (s, 4H); MS (ESI+): m/z=247.1 [M+H]+. 1,10-Phenanthroline-2,9-dicarbohydrazide (L4) was obtained by the same experimental procedure from 2,9-dimethyl-1,10-phenanthroline-2,9-dicarboxylate (which is obtained as described by C. Chandler et al., J Heterocycl Chem 1981, 18, 599□601). Yield 2.38 g (80%). Pale yellow solid; 1H NMR (300 MHz, DMSO-d6): δ=10.77 (s, 2H), 8.69 (d, J=8.3 Hz, 2H), 8.40 (d, J=8.3 Hz, 2H), 8.14 (s, 2H), 4.78 (s, 4H). MS (ESI+): m/z=297.2 [M+H]+. I.2 Synthesis of bis(acylhydrazone) Precursors (Compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) N′2,N′6-Bis(pyridin-4-ylmethylene)pyridine-2,6-dicarbohydrazide (1): A solution of pyridine-2,6-dicarbohydrazide L1 (390 mg, 2.0 mmol) and pyridine-4-carbaldehyde (471 mg, 4.4 mmol, 0.414 mL) in ethanol (10 mL) was heated under reflux for 18 h. After cooling, the precipitate was collected by filtration, washed with ethanol, and dried, to give compound 1 (672 mg, 90%) as a white powder. 1H NMR (300 MHz, DMSO-d6): δ=12.54 (s, 2H), 8.79 (s, 2H), 8.72 (d, J=5.9 Hz, 4H), 8.44□8.25 (m, 3H), 7.77 (d, J=6.0 Hz, 4H); MS (ESI+): m/z=374.2 [M+H]+, 187.6 [M+2H]2+. N′2,N′6-Bis(quinolin-4-ylmethylene)pyridine-2,6-dicarbohydrazide (2): Was obtained by following the same experimental procedure in 93% yield from pyridine-2,6-dicarbohydrazide L1 and quinoline-4-carbaldehyde. Pale-yellow solid; 1H RMN (300 MHz, DMSO-d6): δ=12.65 (s, 2H), 9.48 (s, 2H), 9.07 (d, J=4.5 Hz, 2H), 8.91 (dd, J=8.4, 0.7 Hz, 2H), 8.53□18.33 (m, 3H), 8.16 (dd, J=8.3, 0.7 Hz, 2H), 7.99 (d, J=4.5 Hz, 2H), 7.92□7.79 (m, 4H); MS (ESI+): m/z=474.3 [M+H]+. N′2,N′6-Bis(quinolin-6-ylmethylene)pyridine-2,6-dicarbohydrazide (3): Was obtained by following the same experimental procedure in 80% yield from pyridine-2,6-dicarbohydrazide L1 and quinoline-6-carbaldehyde. Pale-yellow solid; 1H NMR (300 MHz, DMSO-d6): δ=12.50 (s, 2H), 9.01-8.94 (m, 4H), 8.52 (d, J=7.8 Hz, 2H), 8.46□8.39 (m, 2H), 8.39□8.28 (m, 5H), 8.13 (d, J=8.8 Hz, 2H), 7.63 (dd, J=8.3, 4.3 Hz, 2H); MS (ESI+): m/z=474.3 [M+H]+, 237.7 [M+2H]2+. N′4,N′6-Bis(pyridin-4-ylmethylene)pyrimidine-4,6-dicarbohydrazide (4): Was obtained by following the same experimental procedure in 99% yield from pyrimidine-4,6-dicarbohydrazide L2 and pyridine-4-carbaldehyde. White solid; 1H NMR (300 MHz, DMSO-d6): δ=12.79 (s, 2H), 9.59 (d, J=0.8 Hz, 1H), 8.71 (s, 2H), 8.69 (d, J=5.8 Hz, 4H), 8.61 (d, J=0.8 Hz, 1H), 7.70 (d, J=5.8 Hz, 4H); MS (ESI+): m/z=375.2 [M+H]+, 188.1 [M+2H]2+. N′4,N′6-Bis(quinolin-4-ylmethylene)pyrimidine-4,6-dicarbohydrazide (5): Was obtained by following the same experimental procedure in 99% yield from pyrimidine-4,6-dicarbohydrazide L2 and quinoline-4-carbaldehyde. Pale-yellow solid; 1H NMR (300 MHz, DMSO-d6): δ=12.86 (s, 2H), 9.67 (s, 1H), 9.48 (s, 2H), 9.04 (d, J=4.3 Hz, 2H), 8.80□8.65 (m, 3H), 8.14 (d, J=8.3 Hz, 2H), 7.95□7.72 (m, 6H); MS (ESI+): m/z=475.3 [M+H]+, 238.2 [M+2H]2+. N′4,N′6-Bis(quinolin-6-ylmethylene)pyrimidine-4,6-dicarbohydrazide (6): Was obtained by following the same experimental procedure in 99% yield from pyrimidine-4,6-dicarbohydrazide L2 and quinoline-6-carbaldehyde. Pale-yellow solid; 1H NMR (300 MHz, DMSO-d6): δ=12.68 (s, 2H), 9.60 (s, 1H), 9.03-8.87 (m, 4H), 8.65 (s, 1H), 8.51 (d, J=8.0 Hz, 2H), 8.32□8.20 (m, 4H), 8.10 (d, J=8.4 Hz, 2H), 7.66□7.55 (m, 2H); MS
{'bibliographic_information': "{'country': 'US', 'doc-number': '17045049', 'kind': 'B2', 'date': '20190403', 'extension': '15', 'invention_title': 'Hydrazone derivatives for preventing or treating EBV-related cancers'}", 'source_file': './grant/2022/ipg220809.xml', 'source_data': 'USPTO-Grant'}